OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
NICE Chief Exec to Stand Down
The chief executive of the National Institute for Health and Care Excellence (NICE), Sir Andrew Dillon, has announced he will be stepping down from his post at the end of March 2020.
The chief executive of the National Institute for Health and Care Excellence (NICE), Sir Andrew Dillon, has announced he will be stepping down from his post at the end of March 2020, after more than two decades of service.
“It has been a privilege to lead the organisation through its first two decades,” said Dillon in an Aug. 22, 2019 press release. “NICE has made a significant contribution to improving outcomes for people using the health and care services, and to the efficient use of resources. I feel very proud to be associated with those achievements.”
“Sir Andrew Dillon has made an immeasurable contribution to the NHS during his 20 years as chief executive of NICE,” added health secretary Matt Hancock in the press release. “Under his leadership, NICE has become the world’s leading authority for providing clinicians and government with independent, clinical evidence about the effectiveness of treatments and medicines. This has been central to building the UK into the world-leader in life sciences and innovative treatments that it is today.”
“Sir Andrew has led NICE with a laser focus on establishing how the latest medicines can benefit patients and the NHS. He has played a central role in building the credibility of the organisation, insisting on transparent processes, and a continuous dialogue with all stakeholders, recognizing that as the science evolves, NICE needs to evolve too,” said Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry. “As a result of this leadership, there is a consensus across industry about the central role of NICE in assessing all medicines, ensuring that patients have a right to access the treatments they need.”
